Treatment of apathy in Parkinson's disease: A bayesian network meta-analysis of randomised controlled trials

Abstract

BackgroundApathy is an important but unrecognised aspect of Parkinson's disease (PD). The optimal therapeutic options for apathy remain unclear. Early recognition and treatment of apathy can reduce the significant burden of disease for patients and their caregivers. Here we conducted a meta-analysis to evaluate the comparative efficacy of different treatment modalities of apathy in PD (CRD42021292099). MethodsWe screened Medline, Embase, and PsycINFO databases for articles on therapies for apathy in PD. The outcome of interest is the reduction in apathy scores post-intervention and is measured by standardised mean differences (SMD) with 95% credible intervals (CrI). We included only randomised controlled trials examining interventions targeted at reducing apathy. ResultsNineteen studies involving 2372 patients were included in the quantitative analysis. The network meta-analysis found pharmacotherapy to be the most efficacious treatment, significantly better than brain stimulation (SMD -0.43, 95% CrI −0.78 to −0.07), exercise-based interventions (SMD -0.66, 95% CrI −1.25 to −0.08), supplements (SMD -0.33, 95% CrI −0.67 to 0), and placebo (SMD -0.38, 95% CrI −0.56 to −0.23). Subgroup analysis of pharmacotherapy versus placebo found similar efficacy of dopamine agonists (SMD -0.36, 95% CI -0.59 to −0.12, P = 0.003) and alternative medications (SMD -0.42, 95% CI -0.61 to −0.23, P < 0.001). The remaining comparisons and subgroup analyses did not demonstrate any significant treatment effects. ConclusionOur meta-analysis of randomised controlled trials showed that pharmacotherapy is the most efficacious treatment option, with dopamine agonists having similar efficacy as other medications. Further research is needed to determine the optimal management strategy.